Menu PATIENTS AND PHYSICIANS Seres is working to develop safe, effective, oral therapies for C. difficile, ulcerative colitis and other serious diseases. Seres’ microbiome therapeutics represent a transformative new approach to medicine In recent years, scientific research has revealed the many essential roles played by the human microbiome — that is, the trillions of microbes that live in or on your body. The gastrointestinal microbiome, specifically, has been found to play a central role in human health. Conversely, a growing body of evidence also indicates that individuals who are missing certain microbiome-provided functions are at an increased risk for diseases such as C. difficile infection and ulcerative colitis, or may respond poorly to treatments for other diseases, such as cancer. Seres’ microbiome therapeutics are designed to modulate key functions by altering the makeup of the gut microbiome. Our oral investigational therapeutic candidates are composed of live bacteria that can induce durable change in the microbiome. Your browser does not support the video tag. A healthy microbiome performs numerous beneficial functions throughout the body. ULCERATIVE COLITIS METASTATIC MELANOMA FAQ C. difficile infection Seres has announced positive topline results in the Phase 3 ECOSPOR III study of SER-109 in the treatment of C. difficile. Seres has completed enrollment in the SERES-013 ECOSPOR IV open-label study for SER-109. Clostridioides difficile, formerly known as Clostridium difficile, or C. difficile, is one of the top three most urgent bacterial threats in the United States, according to the Centers for Disease Control. It is the leading cause of hospital-acquired infection in the U.S. and is responsible for the deaths of approximately 20,000 Americans each year. The current standard of care for C. difficile infection is antibiotic treatment. However, antibiotic treatment alone is ineffective against dormant spore forms of C. difficile, which can germinate and grow after antibiotics are completed, leading to a vicious cycle of recurrence. Repeated antibiotic exposure also depletes beneficial bacteria that inhibit C. difficile, increasing the risk of recurrence. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection. The FDA has granted SER-109 both Breakthrough Therapy and Orphan Drug designations. Clinical trials in C. difficile Expanded Access/Compassionate Use About SER-109 Resources for patients C. DIFFICILE METASTATIC MELANOMA FAQ Ulcerative colitis Now enrolling: A Phase 1b study in Australia and New Zealand for patients with mild-to-moderate ulcerative colitis. Learn more: http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380059 Ulcerative colitis (UC) is a serious chronic condition marked by persistent inflammation in the digestive tract which can greatly reduce an individual’s quality of life. Although the pathogenesis of UC remains unclear, changes in the gastrointestinal microbiome and associated metabolites appear to be important. The relationship between the immune system and the gut microbiome also appears to play a role in the disease. There is a clear need for new treatments for patients with mild-to-moderate UC. Anti-inflammatory compounds like 5-ASAs are used to reduce inflammation in mild-to-moderate UC patients, but they fail to induce remission in a significant proportion of patients. Corticosteroids are used to dampen the immune system and control flare-ups, but they carry toxicity risks that limit their long-term use. Patients who do not respond to early-stage treatments are likely to advance to biologic drugs and small molecules, which bring a high risk of side effects and may require IV delivery. Seres has completed enrollment of a clinical trial of SER-287, an oral consortium of commensal bacteria designed to have pharmacological effects on the pathways driving UC. Clinical trials in ulcerative colitis About SER-287 About SER-301 Resources for patients Scientific literature ULCERATIVE COLITIS C. DIFFICILE FAQ Metastatic melanoma Cancer treatments that work by turning the immune system against cancer, such as checkpoint inhibitors and other immunotherapies, only work for an estimated 20-30% of treated patients. One factor in a patient’s response appears to be the makeup of his or her gut microbiome. In collaboration with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, Seres has identified a microbiome signature that correlates with patients’ response to therapy across a number of different types of cancer. Scientific literature ULCERATIVE COLITIS C. DIFFICILE METASTATIC MELANOMA Frequently asked questions What are Seres' microbiome therapeutics, and how are they different from probiotics? How are Seres’ drugs different from fecal microbiota transplantation (FMT)? What are the safety steps within Seres’ manufacturing process for SER-109 and SER-287? What are the safety steps within Seres’ manufacturing process for SER-301 and SER-155? © 2021 Seres Therapeutics Privacy Policy Terms of use Follow us on Linkedin Follow us on Twitter Follow us on Facebook